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ORIGINAL STUDIES

Comparative differences of mitral valve-in-valve implantation:
A new mitral bioprosthesis versus current mosaic and epic
valves
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Abstract
Objective: Evaluate transcatheter mitral valve replacement (TMVR) valve-in-valve
(VIV) outcomes in three different mitral bioprostheses (of comparable measured
internal diameters) under stable hemodynamic and surgical conditions by bench,
echocardiographic, computerized tomography (CT), and autopsy comparisons preand post-valve implantation in a porcine model under matched controlled conditions.
Background: Impact of surgical bioprosthesis design on TMVR VIV procedures is
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ing. Twelve had consistent anatomic features and underwent implantation of mitral

Methods: Fifteen similar-sized Yorkshire pigs underwent pre-procedural CT screenbioprostheses. Four valves from each of three manufacturers were implanted in randomized fashion: 27-mm Epic, 27-mm Mosaic, and 25-mm Mitris, followed by TMVR
VIV with 26 Edwards Sapien3. Post-VIV, suprasternal TEE studies were performed to
assess hemodynamic function, followed by a gated contrast CT. After euthanasia, ani-

Funding information
Edwards Lifesciences Corp to Synchrony Labs.

mals underwent necropsy for anatomic evaluation.
Results: All 12 animals had successful VIV implantation with no study deaths. The
post vivMitris (3.77 ± 0.36)/(2.2 ± 0.25 mmHg) had the lowest peak/mean transmitral gradient and the vivEpic the highest (15.5 ± 2.55)/(7.09 ± 1.13 mmHg). All
THVs (transcatheter heart valves) had greatest deformation within the center of the
THV frame; with the smallest waist opening area in the vivEpic (329 ± 35.8 mm2) and
greatest in the vivMitris (414 ± 33.12 mm2). Bioprosthetic frames without obvious
radiopaque markers resulted in the most ventricular implantation of the THV's
anteroseptal frame (Epic:
prosthesis (Mitris:

4.52 ± 0.76 mm), versus the most radiopaque bio-

1.18 ± 2.95 mm), and higher peak LVOT gradients (Epic: 4.82

± 1.61 mmHg; Mitris: 2.91 ± 1.47 mmHg).
Conclusions: The current study demonstrates marked variations in hemodynamics,
THV opening area, and anatomic dimensions among measured similarly sized mitral
Abbreviations: CT, computed tomography; LVOT, left ventricular outflow tract; THV, transcatheter heart valve; TMVR, transcatheter mitral valve replacement; VIV, valve-in-valve.
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bioprostheses. These data suggest a critical need for understanding the potential
impact of variations in bioprosthesis design on TMVR VIV clinical outcomes.
KEYWORDS

computed tomography, left ventricular outflow tract, transcatheter mitral valve replacement
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into this study. All animals underwent baseline physical exam
screening with on-site veterinary examination at Synchrony Labs

Bioprosthetic surgical mitral valves have a finite lifespan. Structural

(Synchrony Labs LLC, Chapel Hill, NC). This study was supported

deterioration requiring redo mitral valve operation occurs in up-to

by Edwards Lifesciences to Synchrony Labs. The funders had no

35% of patients within 10 years of implantation.1,2 Redo mitral valve

role in the study design, data collection and analysis, decision to

surgery is associated with high perioperative morbidity and mortal-

publish, or preparation of the manuscript. Study design, evalua-

ity.

2,3

Given reports of postsurgical redo operation in-hospital mortal-

tion, and implementation were performed by the Cardiovascular

ity rates upwards of 12%, many patients with high STS risk scores are

Masters Consortium, LLC (CMC). The CMC is an independent

deemed ineligible for redo intervention.2,4 In patients with degenera-

group of physicians in the fields of interventional cardiology,

tive surgical mitral valves, transcatheter mitral valve replacement

interventional imaging, and cardiac surgery who objectively assess

(TMVR) valve-in-valve (VIV) options have emerged as safe and feasi-

new cardiovascular technologies using scientifically designed pre-

ble alternatives for patients at high operative risk for redo mitral sur-

clinical and clinical studies. The study protocol was approved by

gery.1,4

the Institutional Animal Care and Use Committee of Synchrony

Transcatheter mitral valve replacement VIV technology is in its

Labs (Synchrony Labs LLC, Durham, NC) and all animals received

4

infancy. There are varying modes of structural valve deterioration.

humane care in compliance with the Guide for the Care and Use of

However, there is little published literature on differences in out-

Laboratory Animals.8

comes of TMVR VIV by types of bioprosthesis or mode of degenera-

TMVR VIV study primary endpoints were defined according to

tion.5,6 There is additionally little published literature documenting

the Mitral Valve Academic Research Consortium (MVARC) criteria

surgical prosthesis variables that may contribute to the success or fail-

for technical, device, and procedural success.6 Secondary endpoints

ure of TMVR VIV. Surgical prosthesis device sizing and valve selection

evaluated specific VIV structurally related technical failure and com-

are still not well understood.7 In 2019, the Valve Labeling Taskforce

plications. This included presence or absence of any THV structural

identified inconsistent definitions of surgical prosthesis labeled sizing,

deformation, device positioning, and TMVR VIV impact on left ven-

inconsistencies between valve sizer dimensions and manufacturer

tricular

labeled prosthesis sizing as complex issues necessitating important

≥10 mmHg from baseline).6 THV frame deformation was assessed

regulatory evaluation.7 To date, no recent controlled study has evalu-

at three points within each device: the atrial portion of the THV,

ated the acute safety, durability, and function of a standard sized

smallest waist of the THV, and the ventricular portion of the THV.

transcatheter heart valve (THV) implanted in similar-sized surgical

The THV opening area was defined as the measured dimensions of

mitral bioprostheses in a head-to-head comparison study. In human

the THV stent frame that corresponded to the dimensions of the

clinical trials and registry data reporting, these studies are not feasible

THV within the bioprosthesis of interest by multi-planar 3D-CT

due to the small number of patients anatomically qualifying for TMVR.

analysis.

outflow

tract

(LVOT)

obstruction

(gradient

increase

Additionally, it is difficult for clinical TMVR VIV studies to compare
different surgical mitral valve designs in the presence of major human
anatomic and hemodynamic variations, variation in modes of struc-

2.1
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Animal preparation and examination

tural valve deterioration, and patient-specific co-morbidities. The aim
of this controlled preclinical experimental study is to evaluate the out-

Prior to procedural consideration, all animals underwent anatomical

comes of TMVR VIV in three surgical mitral bioprostheses of compa-

screening by contrast-enhanced retrospective electrocardiographic

rable measured internal diameters in a head-to-head comparison of

gated computed tomography (CT) scanning with the on-site Siemens

acute THV function post-TMVR VIV in the setting of controlled ana-

scanner (Siemens Dual Somatom, Siemens Medical, Forchheim,

tomic sizing, hemodynamic conditions, and transcatheter expertise.

Germany).9 Pre-procedural screening focused on anatomical characteristics relevant to physicians in the clinical setting. These data
focused on left atrial size, mitral annulus dimensions, left ventricular

2
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METHODS

function, and potential transseptal catheter crossing height. Those
animals with transseptal crossing heights ≤15 mm or mitral annular

Between August 2020 and January 2021, 15 Yorkshire pigs

dimensions with >6% variation from other study animals were

underwent anatomical screening for consideration for enrollment

excluded. Twelve pigs met study inclusion criteria.

3
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We performed bench measurements of all labeled sizes of mitral

2.4

|

Data collection and statistics

bioprostheses of interest, the Epic (Abbott, Abbott Park, IL), Mosaic
(Medtronic, Minneapolis, MN), and Mitris (Edwards Lifesciences,

Pre-procedure (anesthetized but unoperated) multi-detector retro-

Irvine, CA) valves (Figure S1 and Table S1). Inner to inner surgical

spectively gated contrast enhanced CT scans were performed on all

frame dimensions were captured at multiple levels within the bio-

animals. Multiphasic CT image reconstructions were performed at

prosthesis frame. Surgical valve size selection was determined based

1.5-mm intervals. Images were transferred in DICOM (Digital Imaging

on grouping of similar internal bioprosthesis frame dimensions, and

and Communications in Medicine) format to off-line computer sta-

not manufacturer labeled device sizing.10

tions for further processing. CT segmentation and analysis was per-

Surgical bioprosthesis implantation was performed same day of

formed using Vitrea (Vital Images, Minnetonka, MN) and Mimics

VIV TMVR by two surgeons blinded to the type of surgical prosthesis

(Materialise, Leuven, Belgium) software. All study animals were eutha-

10

Until time of THV

nized and underwent on-site supervised necropsy with cardiac

implantation, the two implanting interventional cardiologists (BPO,

explantation for anatomical evaluation of each THV. Given the small

WWO) were blinded to type of surgical prosthesis to be implanted in

sample size, descriptive data are presented with no further statistical

each procedure. Surgical valves were performed in randomized order

analysis. Continuous and categorical variables are defined as mean

between the interventional cardiologists with all three valves

and standard deviation; discrete variables are presented as numbers

implanted by each interventionalist to minimize operator variability

and percentages.

being implanted until time of surgical procedure.

for all three surgical mitral bioprostheses. Echocardiographic, suprasternal TEE, and periprocedural CT imaging was performed by the
same interventional imaging physician across all three TMVR VIV pro-

3
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cedures in all phases of device interrogation utilizing the 27-mm
Abbott Epic, the 27-mm Medtronic Mosaic, and the 25-mm Edwards

Fifteen animals underwent rigorous pre-procedural CT anatomical

Mitris.

screening. All animals were screened to ensure the most accurate anatomic sizing of key cardiac chambers, mitral annulus dimensions, and
feasibility of transseptal crossing height for VIV TMVR. Three animals

2.2

|

TMVR VIV procedure

were excluded due to >6% variation of mitral annular dimensions, or
transseptal crossing height ≤ 15 mm as evaluated by CT.

VIV TMVR was performed according to previously published techniques for transseptal mitral VIV.11 All animals underwent transseptal
access via suprasternal TEE probe guidance and received intravenous

3.1

|

Study population characteristics

heparin during the procedure to maintain an activated clotting time >
250 s. Under fluoroscopic and TEE guidance, the THV was positioned

Baseline animal procedural anatomical evaluation parameters are

within the confines of the surgical mitral bioprosthesis to minimize

documented in Table 1. There was <6% anatomical variation among

any risk of LVOT obstruction and deployed under rapid pacing with

all study animals. The mean mitral annulus area was 1410.00

slow controlled balloon inflation.11 The same VIV delivery technique

± 133.60 mm2, with mean left atrial width of 43.64 ± 2.08 mm, left

and

atrial height of 28.87 ± 1.93 mm, and mean transseptal crossing

balloon

inflation

methodology

was

applied

across

all

implanted THV.

height of 20.53 ± 1.48 mm. Mean commissure to commissure distance of native mitral annuli was 41.56 ± 1.82 mm, with mean anterior to posterior distance of 37.78 ± 1.72 mm.

2.3

|

Post-TMVR VIV evaluation

Baseline post-surgical bioprosthesis hemodynamic and echocardiographic data were similar among all 12 study animals (Table 2).

Epicardial echocardiograms were obtained according to standard of

Post-surgical bioprosthesis mitral valve peak gradients averaged 7.23

care guidelines according to the American Society of Echocardiog-

± 3.38 mmHg, mean gradient 3.82 ± 1.76 mmHg, and LVOT peak gra-

12

Suprasternal echocardiographic imaging

dients averaged 3.29 ± 1.42 mmHg (mean 1.54 ± 0.60 mmHg). All

was performed using a standard TEE probe inserted via sup-

study animals had normal LV function at post-surgical valve implant

rasternal cutdown posterior to the cardiac silhouette. To ensure

(Table 2). By epicardial echocardiographic evaluation, no animal had

reproducibility of all echocardiographic evaluation, hemodynamic

underlying evidence of LVOT obstruction. Three of four Epic

stability was maintained for all studies, with an effort to capture all

bioprostheses were noted to have an eccentric paravalvular leak at

study variables at similar heart rate, and blood pressure points. Fol-

the anterolateral commissure. All other post-implantation mitral

lowing TMVR VIV procedure, all study animals were transported to

bioprostheses had no central or paravalvular leaks. All mitral

on-site Siemens CT scanner for a contrast ECG-gated retrospective

bioprostheses were noted to have normal leaflet function and coapta-

scan for evaluation of THV function, post-TMVR VIV neo-LVOT,

tion without evidence of stenosis. All TMVR VIV procedures achieved

and

device implantation technical success; there were no valve

raphy recommendations.

assessment

of

device

described methodologies.13

landing

zone

utilizing

previously

embolizations.
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TABLE 1

Baseline porcine demographic information and CT screening anatomical information
Epic

Mosaic

Mitris

Age at implant (days)

169.8 ± 27.2

165.5 ± 22.8

Weight at implant (kg)

88.0 ± 8.95

89.3 ± 6.26

Mitral annulus area (sq mm)

1436.75 ± 131.18 (vs. Mitris 1.5% variation) 1349.00 ± 100.62 (vs. Mitris 4.79%)

Mitral annulus circumference (mm)

148.8 ± 7.6
85.0 ± 6.89
1415.25 ± 152.02

139 ± 7.75 (vs. Mitris 1.45% variation)

133.75 ± 5.38 (vs. Mitris 2.40% variation)

137.0 ± 7.53

Mitral annulus commissure to
commissure distance (mm)

42.70 ± 1.23 (vs. Mitris 2.01% variation)

40.35 ± 1.31 (vs. Mitris 3.65% variation)

41.85 ± 2.72

Mitral annulus anterior to posterior
distance (mm)

37.35 ± 1.79 (vs. Mitris 0.75% variation)

38.1 ± 1.0 (vs. Mitris 1.24% variation)

37.63 ± 2.27

Left atrium width (mm)

43.13 ± 2.79 (vs. Mitris 0.30% variation)

44.80 ± 1.40 (vs. Mitris 4.10% variation)

43.0 ± 2.20

Left atrium height (mm)

28.35 ± 1.12 (vs. Mitris 0.46% variation)

29.78 ± 3.17 (vs. Mitris 4.46% variation)

28.48 ± 1.41

Transseptal crossing height (mm)

19.80 ± 1.49 (vs. Mitris 5.55% variation)

20.85 ± 1.36 (vs. Mitris 0.38% variation)

20.93 ± 1.90

Frequency of circumflex artery
coursing close to mitral annulus

One out of four pigs

Two out of four pigs

Four out of four pigs

Note: From Wang et al.10

T A B L E 2 Hemodynamics at time of echocardiographic data capture with concomitant baseline post-surgical implantation echocardiographic
measurements
EPIC
Post-surgical valve implant Systolic blood pressure
Diastolic blood pressure
Heart rate
Left ventricle ejection
fraction

Post-TMVR VIV implant

Mosaic

92.5 ± 9.85 (vs. Mitris 0.53% variation) 91.25 ± 8.81 (vs. Mitris 1.9% variation)
59.0 ± 7.53

64.75 ± 8.73

MITRIS
93 ± 12.65
62.5 ± 8.96

92.5 ± 11.27 (vs. Mitris 3.9% variation) 89.8 ± 9.29 (vs. Mitris 0.89% variation) 89.0 ± 10.55
>55%

>55%

>55%

Mitral valve peak gradient
(mmHg)

9.17 ± 3.72

7.2 ± 4.11

5.05 ± 2.67

Mitral valve mean gradient
(mmHg)

4.59 ± 1.90

3.92 ± 2.40

2.61 ± 1.26

LVOT peak gradient

3.42 ± 1.31

4.40 ± 1.25

2.06 ± 1.05

LVOT mean gradient

1.72 ± 0.63

1.86 ± 0.47

1.04 ± 0.55

Systolic blood pressure

86.25 ± 14.57 (vs. Mitris 2.3% variation) 81.75 ± 13.87 (vs. Mitris 7.6% variation) 88.25 ± 11.5

Diastolic blood pressure

53.25 ± 5.25

Heart rate

50.75 ± 11.62

44.25 ± 6.9

95.5 ± 11.68 (vs. Mitris 6.2% variation) 85.75 ± 9.25 (vs. Mitris 4.6% variation) 89.75 ± 12.31

Note: Data from post-surgical valve implant are from Wang et al.10

3.2 | Comparison of valve prosthesis type: Major
safety, technical, and mechanistic endpoints

Transcatheter heart valve frame dimensions were obtained at multiple levels by multi-planar 3D reconstruction of the post-TMVR VIV CT
images (Table 3). THV frame dimensions were documented at the atrial

3.2.1

|

Imaging measurements

opening of the THV, the narrowest portion of the THV frame defined as
the “waist” of the THV within the surgical mitral bioprosthesis, and again

Post-TMVR VIV echocardiographic findings are depicted in Table 3.

at the most ventricular portion of the frame of the THV in the LVOT.

Among the three types of mitral bioprostheses, the TMVR VIV in the

THV frame dimensions impacted transmitral Doppler echocardio-

27 mm-Epic (vivEpic) had the highest peak/mean mitral gradient,

graphic gradients. Multi-planar 3D CT images demonstrated the viv-

followed by the TMVR VIV in 27-mm Mosaic (vivMosaic), while the

Epic to have the smallest THV atrial opening area (396.00

TMVR VIV in the 25-mm Mitris (vivMitris) had the least mitral peak/

± 42.88 mm2), smallest THV waist opening area (329.00 ± 35.8 mm2),

mean gradient (Table 3). There was no evidence of paravalvular leak

and the highest peak/mean mitral gradient (15.50 ± 2.55)/(7.09

between the frame of the implanted THV and the surgical bio-

± 1.13 mmHg). The vivMitris had the largest THV opening area

prosthesis on any implant.

(428.00 ± 47.9 mm2), largest THV waist opening area (414.00

5
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TABLE 3

Transcatheter valve function post TMVR VIV
EPIC (27 mm)

Mosaic (27 mm)

TMVR VIV atrial opening max internal dimensions
(mm)

21.8 ± 1.06

22.3 ± 0.88

22.85 ± 0.91

TMVR VIV atrial opening min internal dimensions
(mm)

21.06 ± 1.33

21.58 ± 1.09

22.53 ± 0.83

TMVR VIV atrial opening surface area (mm2)
TMVR VIV atrial opening circumference (mm)

396 ± 42.88

414.5 ± 27.96

MITRIS (25 mm)

428 ± 47.9

70.5 ± 3.79

72.5 ± 2.52

73.5 ± 4.20

20.03 ± 1.05

20.5 ± 0.25

22.48 ± 1.24

TMVR VIV waist minimal internal dimensions (mm)

19.6 ± 0.70

19.98 ± 0.56

21.7 ± 0.82

TMVR VIV waist opening surface area (mm2)

329 ± 35.80

TMVR VIV waist max internal dimensions (mm)

TMVR VIV waist opening circumference (mm)

347 ± 17.66

414 ± 33.12

64.25 ± 3.59

66 ± 1.83

72 ± 3.16

TMVR VIV ventricular opening max internal
dimensions (mm)

24.0 ± 1.13

23.95 ± 0.56

23.75 ± 0.58

TMVR VIV ventricular opening min internal
dimensions (mm)

23.38 ± 0.50

22.68 ± 1.36

23.45 ± 0.93

TMVR VIV ventricular opening area (mm2)

471.5 ± 39.52

468.25 ± 39.02

473.5 ± 27.87

76.75 ± 2.99

77.25 ± 2.22

TMVR VIV ventricular opening circumference (mm)

77 ± 2.94

Post TMVR VIV mitral peak gradient (mmHg)

15.5 ± 2.55

9.97 ± 3.19

3.77 ± 0.36

Post TMVR VIV mitral mean gradient (mmHg)

7.09 ± 1.13

5.32 ± 1.31

2.2 ± 0.25

Note: Transcatheter valve dimensions by CT versus Doppler parameters of TMVR VIV function (see corresponding Figure 1).

F I G U R E 1 Post-TMVR VIV variation in 26S3 frame expansion among different bioprostheses. Row (A) demonstrates greater restriction of
the 26S3 THV's ability to fully expand within its atrial dimensions in the Epic and the Mosaic as compared to the Mitris bioprosthesis. Row
(B) demonstrates the 3D contour and constraint at the waist (red arrow) of the 26S3 that is present more prominently in the Epic and Mosaic
bioprostheses as compared to the Mitris. Row C necropsy images of the explanted 26S3 confirms the post-TMVR VIV CT findings demonstrating
atrial and waist landing zone constraint of the THV in different bioprostheses. CAD, computer-aided-design; LA, left atrium; LV, left ventricle;
THV, transcatheter heart valve; TMVR, transcatheter mitral valve replacement; VIV, valve-in-valve [Color figure can be viewed at
wileyonlinelibrary.com]

6
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TABLE 4

TMVR VIV depth of protrusion versus hemodynamics
Epic (27 mm)

Mosaic (27 mm)

Mitris (25 mm)

Transcatheter heart valve depth of protrusion in LV
at anteroseptal surgical strut (mm)

4.52 ± 0.76

4.19 ± 0.85

1.18 ± 2.95

Transcatheter heart valve depth of protrusion in LV
at anterolateral surgical strut (mm)

4.37 ± 2.98

1.26 ± 0.59

0.27 ± 2.88

Transcatheter heart valve depth of protrusion in LV
at posterior surgical strut (mm)

2.29 ± 1.64

2.78 ± 1.08

0.53 ± 2.18

247.34 ± 31.0

223.22 ± 26.42

225.07 ± 56.63

191.06 ± 34.76

191.16 ± 6.0

201.47 ± 40.57

Predicted VIV Neo-LVOT area (in mm2)
2

Actual post post-TMVR VIV Neo-LVOT area (in mm )

56.28 ± 40.93

32.06 ± 25.80

23.6 ± 24.72

LVOT peak gradient (mmHg)

4.82 ± 1.61

3.54 ± 1.30

2.91 ± 1.47

LVOT mean gradient (mmHg)

2.32 ± 0.62

1.57 ± 0.60

1.32 ± 0.55

Difference in predicted and actual post-TMVR VIV
Neo-LVOT area (in mm2)

Note: Comparative evaluation of post transcatheter valve-in-valve left ventricular outflow tract risk (see corresponding Figure 2).
Abbreviations: LV, left ventricle; LVOT, left ventricular outflow tract; VIV, valve-in-valve.

F I G U R E 2 Consistency of TMVR VIV deployment landing zone versus type of bioprosthesis. The TMVR VIV Epic implantation trended
toward greater protrusion into the LVOT across all three surgical struts as compared to the Mosaic and the Mitris bioprostheses. The TMVR VIV
in Mitris demonstrated greatest ability to land within the depth of the bioprosthesis frame across all three surgical struts. Letter 'x' within each
plot depicts the mean marker. TMVR, transcatheter mitral valve replacement; VIV, valve-in-valve [Color figure can be viewed at
wileyonlinelibrary.com]

± 33.12 mm2), and the lowest peak/mean mitral gradient (3.77

3.2.2

|

Risk of LVOT obstruction measures

± 0.36)/(2.20 ± 0.25 mmHg; Figure 1). Compared to the vivEpic and
vivMosaic, the vivMitris was the only THV noted to have a decrease

There was no clinically significant LVOT obstruction in any study ani-

in

(3.77 ± 0.36)/(2.20

mal post-TMVR VIV. Post-TMVR VIV predicted neo-LVOT area was

± 0.25 mmHg) compared to immediate postsurgical bioprosthesis

performed using a 26 Sapien 3 heart valve modeled at depth of

implantation without VIV (5.05 ± 2.67)/(2.61 ± 1.26 mmHg). All other

deployment flush with the distal strut of each mitral bioprosthesis.

VIV prostheses were noted to have an increase between post-surgical

The predicted neo-LVOT and the actual TMVR VIV deployment were

and post-TMVR VIV mitral peak/mean gradients.

intended to be at the same landing zone. Post-VIV procedure, actual

mitral

peak/mean

gradient

post-VIV

7
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F I G U R E 3 Variations in bioprosthesis strut design and impact on TMVR VIV. Pictured on the far left, the TMVR device (yellow bracket) has
greater ventricular protrusion beyond the distal portions of the Epic bioprosthesis as compared to the Mosaic (orange bracket) and Mitris
bioprostheses (white bracket). The Epic bioprosthesis demonstrates a wider strut (yellow star) width than the Mosaic and Mitris bioprosthesis.
VIV, valve-in-valve [Color figure can be viewed at wileyonlinelibrary.com]

F I G U R E 4 Fluoroscopic
visibility of each type of
bioprosthesis. Row
(A) demonstrates the different
bioprostheses' fluoroscopic visibility
by CT. The Epic bioprosthesis has a
light annular rim (orange dashed
arrow) visible at its atrial portion of
the mitral cuff, the Mosaic has
radiopaque circles (black arrows)
within each distal strut. The entire
Mitris frame is radiopaque (black
dashed arrows) and visible under
fluoroscopy. Row (B) demonstrates
the presence or absence of
fluoroscopic landmarks of each
bioprosthesis [Color figure can be
viewed at wileyonlinelibrary.com]

neo-LVOT area was performed using the final landing zone of the
THV. Additionally, 3D multi-planar CT reconstruction was performed

3.3 | Bench measurements: Bioprosthesis design
and impact on THV function

to analyze the depth of transcatheter heart frame stent deployment at
the level of the surgical anteroseptal, anterolateral, and posterior

Surgical prosthesis frame pre-VIV TMVR dimensions were additionally

struts within the LVOT (Table 4).

obtained at the level of the sewing ring, and the ventricular portion of

There was variability in depth of THV implantation among all

the surgical frame (Table S1). Bench surgical prosthesis dimensions

three struts of the surgical mitral bioprostheses. All THVs trended

demonstrated the 27-mm Epic to have the smallest atrial internal

toward having a more ventricular deployment at the level of the

dimensions

anteroseptal strut (Figure 2). The vivEpic had the most ventricular pro-

corresponding to the small post-VIV TMVR atrial frame dimensions

trusion of the THV frame at the anteroseptal ( 4.52 ± 0.76 mm),

(max internal dimension: 21.8 ± 1.06 mm, min internal dimension:

anterolateral ( 4.37 ± 2.98 mm), posterior struts ( 2.29 ± 1.64 mm),

21.06 ± 1.33 mm). Corresponding associations between size of surgi-

and highest peak LVOT gradient (4.82 ± 1.61 mmHg). The vivMitris

cal frame atrial sewing cuff internal dimensions and ability of post-VIV

had the least amount of protrusion beyond the frame of the surgical

THV atrial dimensions to expand remained consistent on CT evalua-

prosthesis struts (anteroseptal strut:

1.18 ± 2.95 mm, anterolateral

tion (Table 3; Table S1).

strut:

0.53 ± 2.18 mm), and smallest

Multiple analyses of surgical strut design were recorded. Bench

peak LVOT gradient (2.91 ± 1.47 mmHg). Visual inspection of the

measurements of surgical strut dimensions were obtained (Table S2).

THV at necropsy confirmed multi-planar CT reconstruction findings

There were no obvious identifiable trends between length of surgical

(Figure 3).

strut protruding into the LVOT and post-TMVR VIV LVOT peak/

0.27 ± 2.88, posterior strut:

at

the

level

of

the

sewing

cuff

(22  22mm),
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mean gradients. Fluoroscopic evaluation of surgical prosthesis and

3 THV within the bioprosthesis, resulting in more laminar flow, opti-

strut design demonstrated variation in prosthesis visibility. In des-

mal THV leaflet opening, less THV leaflet pinwheeling, and smaller

cending order, the most challenging VIV TMVR deployment was in

post-VIV mitral peak/mean gradient than its counterpart the 27-mm

the least fluoroscopically visible 27-mm Epic prosthesis, followed by

Epic and 27-mm Mosaic prostheses.

the 27-mm Mosaic, and most visible was the 25-mm Mitris

Modern mechanisms of transcatheter structural heart valve dete-

(Figure 4). Presence of radiopaque distal strut markers and radi-

rioration have been primarily attributed to presence or absence of

opaque frame was associated with more consistency between

long-term intake of oral anticoagulation.17 This is the first study to

predicted and actual post-TMVR VIV neo-LVOT areas (Figure 4 and

demonstrate, in the absence of any surgical valve structural deteriora-

Table 4).

tion, while on therapeutic anticoagulation, the controlled implantation
of a 26 Sapien 3 was independently associated with higher peak/
mean mitral gradients in the 27-mm Epic, followed by the 27-mm

4

|

DISCUSSION

Mosaic, followed by the 25-mm Mitris. Hence, by default, in the
absence of existing structural valve deterioration, variations in mitral

Porcine models have been utilized extensively for preclinical evalua14–16

peak/mean gradients post-VIV are likely due to differences in surgical

This is the first preclinical head-

device design. In the absence of standardized guidelines on surgical

to-head evaluation of TMVR VIV utilizing a 26 Sapien 3 THV across

bioprostheses' sizing, design, and device selection, physicians must

three different surgical prosthesis design platforms in a controlled

consider each patient's likelihood of requiring a redo VIV procedure

anatomic and hemodynamic environment.

upon surgical structural valve degeneration prior to mitral bio-

tion of prosthetic valve design.

Here, we show that there was a strong connection between (1)

prosthesis implantation. Failure to account for the impact of surgical

transcatheter heart valve atrial and waist opening area to post-TMVR

valve design on future TMVR VIV procedures may increase a patient's

VIV mitral peak/mean gradients, (2)surgical internal frame dimensions

risk of early VIV structural degeneration.

to the degree of THV expansion, and (3)fluoroscopic visibility of mitral
bioprostheses compared to post-TMVR VIV LVOT peak gradient. The
27-mm Epic mitral bioprosthesis, with smallest internal atrial dimen-

5

|

LIM I TAT I ON S

sions, subsequently had the most constrained and narrowing of the
inflow of the atrial dimensions of the THV in the Epic, and even

This acute animal study is limited by small sample size without ability

smaller vivEpic waist THV dimensions, leading to the highest post-

to assess for long-term VIV durability. In the absence of frozen leaf-

TMVR VIV mitral peak/mean gradients. Absence of radiopaque

lets, findings of elevated transmitral peak/mean gradients secondary

markers in the distal struts of the Epic bioprosthesis impaired visuali-

to structural constraints within the surgical bioprostheses have

zation of TMVR VIV landing zones, resulting in greater risk of ventric-

unknown long-term clinical impact. This study demonstrates greater

ular implantation of the THV beyond intended TMVR VIV landing

velocities, and greater resulting turbulent flow in VIV prosthesis with

zone. This lack of fluoroscopic visibility resulted in the 27-mm Epic

the least tubular expansion. To date, the relationship between turbu-

device trending toward higher peak LVOT gradients, than similar-sized

lent Doppler velocities and calculated echocardiographic gradients on

prostheses that had radiopaque distal strut demarcated landing zones.

long-term clinical outcomes of THVs is not yet established. Although

Current TMVR VIV literature observed higher post-VIV mitral

this study rigorously accounted for reproducible anatomic and hemo-

mean gradients to be associated with worse clinical outcomes.4,17 In

dynamic parameters, it serves as a potential outline for future human

the VIVID registry, fewer TMVR VIV devices met the MVARC device

clinical studies. Given the small number of animals in this pilot study,

success criteria primarily due to findings of transmitral mean gradients

all study results should be interpreted as hypothesis generating.

≥5 mmHg post-TMVR VIV.

Larger sample size study populations with long-term follow-up will be

5

Patients with post-TMVR VIV mitral

mean gradients ≥10 mmHg were noted to have higher likelihood of
developing

clinical

symptoms

of

heart

failure

and

necessary to evaluate clinical outcomes.

needing

reintervention.5 Discrepancies in post-VIV mitral mean gradient were
thought to be attributed to the size of THV implanted in the

6

|

CONC LU SION

degenerated bioprosthesis, resulting in suboptimal hemodynamic outcomes, or suboptimal expansion of the THV leading to frozen leaflets,

The impact of surgical prosthesis designs on transcatheter mitral VIV

and less so on surgical frame design.5,17 To date, there is little publi-

biomechanical and hemodynamic function is not well studied. Hetero-

shed literature on the impact of surgical frame design on structural

geneity in surgical prosthesis design may positively or negatively affect

deterioration of the implanted THV.

THV structural form and function. Mitral bioprosthesis device selection

This study is the first to demonstrate that variations in surgical

must consider the patients' potential candidacy for future TMVR VIV

bioprosthesis frame shape, frame radiopacity, and internal frame sizing

procedures upon structural valve deterioration. Implications of this

can all directly impact the form and function of the implanted THV.

study demonstrate a critical need for standardization and scientific

Surgical mitral bioprostheses that were more tubular in shape such as

evaluation of the impact of surgical bioprosthesis design on TMVR VIV

the 25-mm Mitris, had more uniformity in expansion of the 26 Sapien

function to ensure optimal outcomes for clinical human implantation.
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